

Rybrevant (amivantamab-vmjw)

| Override(s) | Approval Duration |
|---------------------|-------------------|
| Prior Authorization | 1 year |

| Medications |
|------------------------------|
| Rybrevant (amivantamab-vmjw) |

APPROVAL CRITERIA

Requests for Rybrevant (amivantamab-vmjw) may be approved if the following criteria are met:

- I. Individual has a diagnosis of recurrent, advanced, or metastatic Non-small Cell Lung Cancer (NSCLC) (Label, NCCN 2A); **AND**
 - II. Lung cancer has epidermal growth factor receptor (EGFR) exon 20 insertion mutations; **AND**
 - III. Individual has disease progression on or after platinum-based chemotherapy; **AND**
 - IV. Individual has not progressed on prior therapy with Rybrevant (amivantamab-vmjw); **AND**
 - V. Individual is using Rybrevant (amivantamab-vmjw) as a single agent;
- OR**
- VI. Individual has a diagnosis of recurrent, advanced, or metastatic Non-small Cell Lung Cancer (NSCLC) (Label, NCCN 1); **AND**
 - VII. Lung cancer has epidermal growth factor receptor (EGFR) exon 20 insertion mutations; **AND**
 - VIII. Individual is using Rybrevant (amivantamab-vmjw) as first-line therapy in combination with carboplatin and pemetrexed;
- OR**
- IX. Individual has a diagnosis of recurrent, advanced, or metastatic Non-small Cell Lung Cancer (NSCLC) (NCCN 1); **AND**
 - X. Lung cancer has epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R S768I, L861Q, and/or G719X mutations; **AND**
 - XI. Individual is using Rybrevant (amivantamab-vmjw) as subsequent therapy in combination with carboplatin and pemetrexed; **AND**
 - XII. Individual has had disease progression on an EGFR tyrosine kinase inhibitor (e.g. Osimertinib);
- OR**

- XIII. Individual has a diagnosis of locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) (Label, NCCN1, 2A); **AND**
- XIV. Lung cancer has epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations; **AND**
- XV. Individual is using Rybrevant (amivantamab-vmjw) as first-line therapy in combination with Lazertinib; **OR**
- XVI. Individual is using as continuation of therapy following disease progression on Rybrevant (amivantamab-vmjw) and lazertinib.

Requests for Rybrevant (amivantamab-vmjw) may not be approved if the above criteria are not met and for all indications not included above.

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2024; Updated periodically.
4. NCCN Clinical Practice Guidelines in Oncology™. © 2023 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on October 8, 2024.
 - a. Non-Small Cell Lung Cancer. V10.2024. Revised September 23, 2024.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.